Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Assets (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Other Non-Current Assets for 7 consecutive years, with $16.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 8.15% to $16.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Dec 2025, down 8.15% year-over-year, with the annual reading at $16.7 million for FY2025, 8.15% down from the prior year.
  • Other Non-Current Assets hit $16.7 million in Q4 2025 for BridgeBio Pharma, down from $25.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $49.8 million in Q2 2021 to a low of $16.6 million in Q1 2025.
  • Historically, Other Non-Current Assets has averaged $25.0 million across 5 years, with a median of $20.7 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: surged 188.61% in 2021 and later crashed 41.21% in 2023.
  • Year by year, Other Non-Current Assets stood at $33.0 million in 2021, then plummeted by 38.77% to $20.2 million in 2022, then increased by 11.87% to $22.6 million in 2023, then fell by 19.58% to $18.2 million in 2024, then decreased by 8.15% to $16.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for BBIO at $16.7 million in Q4 2025, $25.5 million in Q3 2025, and $18.1 million in Q2 2025.